Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012 HEP	Dec. 31, 2011 HEP	Dec. 31, 2010 HEP
Cash flows from operating activities:
Net income	$ 1,760,033	$ 1,059,704	$ 133,051
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	242,868	159,707	117,529
Earnings of equity method investments, net of distributions	701	387	482
Gain on sale of marketable equity securities	(326)	0	0
Deferred income taxes	95,408	(8,860)	23,840
Equity-based compensation expense	39,203	26,825	11,498
Change in fair value – derivative instruments	52,335	306	1,464
(Increase) decrease in current assets:
Accounts receivable	71,627	373,591	43,437
Inventories	(205,013)	(56,828)	(96,854)
Income taxes receivable	19,056	(36,394)	(14,990)
Prepayments and other	(9,366)	(14,214)	369
Increase (decrease) in current liabilities:
Accounts payable	(194,051)	(251,428)	70,279
Income taxes payable	(40,366)	72,091	0
Accrued liabilities	(39,851)	60,467	22,414
Turnaround expenditures	(159,707)	(32,023)	(34,966)
Other, net	30,136	(14,940)	5,702
Net cash provided by operating activities	1,662,687	1,338,391	283,255
Cash flows from investing activities:
Additions to properties, plants and equipment	(290,334)	(158,026)	(103,722)	(44,929)	(216,215)	(109,510)
Increase in cash due to merger with Frontier	0	872,739	0
Investment in Sabine Biofuels	(2,000)	(9,125)	0
Purchases of marketable securities	(671,552)	(561,899)	0
Sales and maturities of marketable securities	297,711	301,020	0
Net cash provided by (used for) investing activities	(711,104)	228,494	(213,232)
Cash flows from financing activities:
Borrowings under credit agreement	0	0	310,000	587,000	118,000	66,000
Repayments under credit agreement	0	0	(310,000)	(366,000)	(77,000)	(113,000)
Net proceeds from issuance of senior notes – HEP				294,750	0	147,540
Principal tender on senior notes	(205,000)	(8,203)	0	(185,000)	0	0
Proceeds from issuance of common units – HEP				0	75,815	0
Purchase of treasury stock	(209,600)	(42,795)	(1,368)		(42,795)	1,368
Structured stock repurchase arrangement	8,620	0	0
Contribution from joint venture partner	6,000	33,500	23,500			23,500
Dividends	(658,085)	(252,133)	(31,868)
Distributions to noncontrolling interest	(58,788)	(50,874)	(48,493)	(58,788)	(50,874)	(48,493)
Excess tax benefit from equity-based compensation	23,361	1,804	(1,094)
Purchase of units for incentive grants – HEP				(5,240)	(1,641)	(2,704)
Deferred financing costs	(3,305)	(11,815)	(3,121)
Other	(1,501)	(1,740)	(910)
Net cash provided by (used for) financing activities	(772,788)	(217,082)	34,482
Cash and cash equivalents:
Increase for the period	178,795	1,349,803	104,505
Beginning of period	1,578,904	229,101	124,596	6,369
End of period	1,757,699	1,578,904	229,101	5,237	6,369
Cash paid during the period for:
Interest	101,709	78,483	66,674
Income taxes	$ 983,618	$ 552,487	$ 62,084